Spyre Therapeutics Inc
NASDAQ:SYRE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.8
34.66
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Spyre Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Spyre Therapeutics Inc
NASDAQ:SYRE
|
2.6B USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395B USD |
4%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
176.5B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
151.9B USD |
28%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.3B USD |
31%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.6B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
84.8B AUD |
19%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR |
43%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
52.8B USD |
1%
|
Spyre Therapeutics Inc
Glance View
Spyre Therapeutics Inc. has positioned itself as a pioneering player in the biopharmaceutical landscape, carving a niche in the rapidly evolving field of gene therapy. Founded with a vision to tackle rare genetic disorders, the company harnesses cutting-edge CRISPR technology to develop precise therapies that can correct genetic mutations at their source. Spyre's business model is predicated on leveraging strategic partnerships with leading research institutions and utilizing its proprietary platforms to streamline the drug development process. By focusing on rare diseases, which often pose significant unmet medical needs, Spyre Therapeutics benefits from the advantages of orphan drug status, including market exclusivity, reducing regulatory hurdles, and commanding premium pricing for its innovative therapies. The company generates revenue primarily through licensing agreements, milestone payments, and royalties from its biotech collaborations. By out-licensing its proprietary technologies and therapeutic candidates, Spyre ensures a steady income stream to fuel its ambitious research and development endeavors. Moreover, its agile business approach allows it to pivot quickly, adapting to new scientific discoveries and market demands, which is critical in the dynamic biotech sector. Additionally, Spyre is exploring direct commercialization pathways for select therapies, eyeing the potential to capture a larger share of the revenue pie, though this comes with the challenge of scaling operations and building robust distribution channels. Overall, Spyre Therapeutics Inc. exemplifies modern resilience and innovation in the biotech industry, continuously finding ways to transform scientific potential into commercial success.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Spyre Therapeutics Inc's most recent financial statements, the company has Net Margin of 0%.